EP
TVTX icon

Eversept Partners’s Travere Therapeutics TVTX Stock Holding History

Eversept Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.4M Buy
798,973
+256,363
+47% +$11.4M 2.35% 12
2026
Q1 		$16.1M Sell
542,610
-632,358
-54% -$18.9M 0.85% 29
2025
Q4 		$44.9M Sell
1,174,968
-242,236
-17% -$7.88M 2.26% 10
2025
Q3 		$33.9M Buy
1,417,204
+102,171
+8% +$1.92M 2.33% 15
2025
Q2 		$19.5M Buy
1,315,033
+498,779
+61% +$8.27M 1.79% 17
2025
Q1 		$14.6M Buy
816,254
+325,958
+66% +$6.62M 1.49% 25
2024
Q4 		$8.54M Sell
490,296
-379,617
-44% -$6.71M 0.76% 27
2024
Q3 		$12.2M Sell
869,913
-221,252
-20% -$2.31M 0.83% 25
2024
Q2 		$8.97M Buy
1,091,165
+135,547
+14% +$913K 0.61% 30
2024
Q1 		$7.37M Buy
+955,618
New +$8.06M 0.49% 38

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's TVTX Position: Q2 2026 in Review

Eversept Partners increased its Travere Therapeutics (TVTX) stake by 47% in Q2 2026, buying an estimated $11.4M and bringing the position to 798,973 shares worth $45.4M. The position accounts for 2.35% of the portfolio, ranked #12.

Eversept Partners first reported a position in TVTX in Q1 2024 and has held it in 10 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Eversept Partners held 798,973 shares of Travere Therapeutics worth $45.4M as of Q2 2026.
  • Eversept Partners bought 256,363 Travere Therapeutics shares in Q2 2026, an estimated $11.4M.
  • Travere Therapeutics made up 2.35% of Eversept Partners's portfolio in Q2 2026, its #12 holding.
  • Eversept Partners first reported a position in Travere Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.